CLX Stock Recent News

CLX posts 57.7% EPS growth and 8% organic sales gain in the fourth quarter, fueled by strong ERP-driven volume increases.

The Clorox Company (NYSE:CLX ) Q4 2025 Earnings Conference Call July 31, 2025 5:00 PM ET Company Participants Linda J. Rendle - CEO & Chairman Lisah Burhan - Vice President of Investor Relations Luc Bellet - Executive VP & CFO Conference Call Participants Andrea Faria Teixeira - JPMorgan Chase & Co, Research Division Anna Jeanne Lizzul - BofA Securities, Research Division Bonnie Lee Herzog - Goldman Sachs Group, Inc., Research Division Christopher Michael Carey - Wells Fargo Securities, LLC, Research Division Filippo Falorni - Citigroup Inc., Research Division Javier T.

Although the revenue and EPS for Clorox (CLX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Clorox (CLX) came out with quarterly earnings of $2.87 per share, beating the Zacks Consensus Estimate of $2.24 per share. This compares to earnings of $1.82 per share a year ago.

Delivers strong margin expansion and adjusted EPS growth for FY25 despite challenging environment in the second half of the fiscal year OAKLAND, Calif. , July 31, 2025 /PRNewswire/ -- The Clorox Company (NYSE: CLX) today reported results for the fourth quarter and fiscal year 2025, which ended June 30, 2025.

OAKLAND, Calif. , July 30, 2025 /PRNewswire/ -- The Clorox Company (NYSE: CLX) announced today that its board of directors has declared an increase to its quarterly dividend from $1.22 to $1.24 per share on the company's common stock.

Beyond analysts' top-and-bottom-line estimates for Clorox (CLX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.

CLX's Q4 performance is likely to have benefited from margin strength and innovation, but macro headwinds and rising costs keep investors cautious.

I'm a dividend investor with a preference for buying well-run companies while they have historically high yields. While I believe this approach helps me build a strong dividend stock portfolio, it often means buying while others are selling.

Clorox (CLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.